Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR013
- Development stage
- Discontinued
- Lead developer
- XenoTherapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Antibody-Based Therapeutics
- Administration
- Ophthalmic, Topical
01
Overview
PR013 is a novel anti-inflammatory and immunomodulatory topical ocular solution developed for the treatment of allergic conjunctivitis. It has demonstrated efficacy in preclinical models comparable to high-dose steroids in reducing redness (hyperemia) and pruritus associated with allergic conjunctivitis. The drug is being evaluated as a topical ophthalmic drop, with clinical studies including a Phase 2 trial assessing its effectiveness and safety compared to vehicle control in patients with allergic conjunctivitis[2][3][4]. The mechanism of action involves anti-inflammatory and immunomodulatory effects, but the precise molecular target has not been disclosed.
Beyond the preview
Go deeper on PR013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR013.